1. Opening Hook
When Barbie went plastic, it made a billion at the box office. When Shaily went plastic (with GLP-1 pens), it made ₹247 crores in a quarter. One’s pink fantasy, the other’s diabetic destiny. But don’t mistake this for a toy story — Shaily just threw in 181% pharma growth and a 28.5% EBITDA margin like it was a weekend hobby. Keep reading, because the sequel may involve 75 million pens, Neo vs Harmony drama, and a cameo by Wegovy.
2. At a Glance
Revenue ₹247 Cr (+38% YoY): Plastic molded into gold.EBITDA ₹70 Cr (+95% YoY): Doubled faster than Maggi cooks.EBITDA Margin 28.5% (+840 bps): CFO finally breathing easy.PAT ₹41 Cr (+136% YoY): Profit sprinted like it had GLP-1 help.Healthcare revenue ₹77 Cr (+181% YoY): GLP-1 pens stole the show.Consumer ₹151 Cr (+14% YoY): FMCG still chugging along.Industrial ₹18 Cr (-6% YoY): Minor hiccup, blamed on timing.
3. Management’s Key Commentary
Quote: “Healthcare segment grew 181% YoY.”(Translation: GLP-1 pens are the new iPhones, and we’re Foxconn.)
Quote: “Effective pen capacity will be 70–75 million by FY27.”(Translation: We’re basically setting up a pen army, just not for exams.)
Quote: “50–60% of capacity backed by customer commitments.”(Translation: Customers pinky-promised, rest is vibes.)
Quote: “Neo likely to be our highest-selling platform over 5 years.”(Translation: Think of it as the iOS of pens, minus the App Store cut.)
Quote: “Injectables will dominate vs oral GLP-1.”(Translation: Pills are Netflix, injectables are cinema halls — still where the action is.)
Quote: “Target is to fully utilize 70–75M capacity by FY28.”(Translation: We’ll get there… unless FDA decides to do a cameo inspection.)
4. Numbers Decoded
Metric Q1 FY26 YoY Change One-Liner Revenue – Total ₹247 Cr +38% Plastic meets healthcare boom. EBITDA – Muscled Up ₹70 Cr +95% Nearly doubled, margins at all-time flex. EBITDA Margin 28.5% +840 bps From average joe to gym trainer. PAT – Sweet Spot ₹41 Cr +136% Sugar-free profits thanks to pens. Healthcare – Star Child ₹77 Cr +181% GLP-1 pens went full blockbuster. Consumer – Old Guard ₹151 Cr +14% Steady FMCG grind, accessories added. Industrial – Sidekick ₹18 Cr -6% Skipped leg day this quarter. Exports 76% of rev Stable Still a global show, not just desi plastic.
5. Analyst Questions
Q: Will effective pen capacity hit 90M by FY27?(Mgmt: Nope, ~70–75M. Translation: Stop exaggerating our gym stats.)
Q: What’s the GLP-1 vs non-GLP-1 sales split?(Mgmt: ~60–65% GLP-1. Translation: Everyone wants the Ozempic pen.)
Q: Any delays in
